Curcumin Nanoparticles Enhance *Mycobacterium bovis* BCG Vaccine Efficacy by Modulating Host Immune Responses

Shaheer Ahmad,* Debapriya Bhattacharya,** Santosh Kar,b Anand Ranganathan,a Luc Van Kaer,c Gobardhan Das*

*a* Special Centre for Molecular Medicine, Jawaharlal Nehru University, New Delhi, India  
*b* Nanoherb Research Laboratory, KIIT TBI, KIIT University, Bhubaneswar, India  
*c* Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA

**ABSTRACT** Tuberculosis (TB) is one of the deadliest diseases, causing ~2 million deaths annually worldwide. *Mycobacterium bovis* bacillus Calmette-Guérin (BCG), the only TB vaccine in common use, is effective against disseminated and meningeal TB in young children but is not effective against adult pulmonary TB. T helper 1 (Th1) cells producing interferon gamma (IFN-γ) and Th17 cells producing interleukin-17 (IL-17) play key roles in host protection against TB, whereas Th2 cells producing IL-4 and regulatory T cells (Tregs) facilitate TB disease progression by inhibiting protective Th1 and Th17 responses. Furthermore, the longevity of vaccine efficacy critically depends on the magnitude of long-lasting central memory T (T<sub>CM</sub>) cell responses. Hence, immunomodulators that promote T<sub>CM</sub> responses of the Th1 and Th17 cell lineages may improve BCG vaccine efficacy. Here, we show that curcumin nanoparticles enhance various antigen-presenting cell (APC) functions, including autophagy, costimulatory activity, and the production of inflammatory cytokines and other mediators. We further show that curcumin nanoparticles enhance the capacity of BCG to induce T<sub>CM</sub> cells of the Th1 and Th17 lineages, which augments host protection against TB infection. Thus, curcumin nanoparticles hold promise for enhancing the efficacy of TB vaccines.

**KEYWORDS** *Mycobacterium tuberculosis*, BCG vaccine, APCs, memory T cells, K<sub>i</sub>1.3 potassium ion channel, curcumin nanoparticles

*Mycobacterium tuberculosis*, the etiological agent of tuberculosis (TB), causes nearly 2 million deaths annually worldwide. One-third of the global population is infected with a latent form of TB, which represents an enormous reservoir waiting for an opportunity to reactivate disease (1). Conditions such as HIV infection that impair immunity may lead to such TB reactivation (2). In the absence of HIV coinfection, only 5 to 10% of latently infected individuals develop TB in their lifetime, whereas 30% of coinfected individuals develop active TB (3). Consequently, a substantial number of deaths in HIV patients are associated with TB infection (4–6). Although one-third of the global population is latently infected with *M. tuberculosis*, the vast majority of individuals are resistant to TB, despite repeated exposure. It is well established that host immune responses play a central role in host resistance against TB. CD4<sup>+</sup> T helper (Th) cells play a key role in protective immunity against TB (7). Previous reports, including studies by our group, have demonstrated that Th1 cells play an important role in host resistance against TB infection (8, 9). However, while the vast majority of TB patients mount Th1 responses, disease continues to progress in many patients (10). These observations indicate that Th1 cell responses are essential but not sufficient for disease protection.

*Mycobacterium bovis* bacillus Calmette-Guérin (BCG) is the only TB vaccine mainly effective against disseminated and meningeal TB in young children; it is likely that the...
host-protective immune responses that it induces diminish over time (11–14). It is well established that long-term memory responses are critically dependent on central memory T (T_{CM}) cells rather than effector memory T (T_{EM}) cells (15). BCG induces both T_{CM} and T_{EM} responses, where T_{EM} responses may play a role in eliminating virulent strains and T_{CM} responses protect against childhood TB but diminish over time. It is well known that BCG immunization promotes the generation of T_{EM} cells, which are the relevant source of T effector cells. These cells predominantly reside in peripheral organs (i.e., the site of infection). However, when the antigen load is gradually reduced, these cells undergo apoptosis. In contrast, T_{CM} cells mostly reside within lymphoid organs and represent a pool of memory T cells for future antigen challenge. Upon antigen reexposure, these cells rapidly proliferate and convert into T_{EM} cells. Heightened production of T_{EM} and T effector cells correlates with the presence of high antigen loads (15). In areas where TB is endemic, the level of exposure to various environmental mycobacteria is also very high. Due to this continuous exposure, most T_{CM} cells differentiate into T_{EM} and T effector cells. Moreover, continuous exposure to environmental antigens eventually causes anergy and exhaustion of antigen-specific T cells (16–18). Consistent with these findings, it is perhaps not surprising that BCG protects children against disseminated TB yet provides little protection against pulmonary TB in adults, who are continuously exposed to environmental mycobacteria (19). Therefore, enhancing the magnitude of T_{CM} cell responses holds promise for improving long-lasting vaccine efficacy. T_{CM} and T_{EM} cells are in a dynamic balance, and their ratio impacts vaccine efficacy. Hence, altering the ratio of these two memory T cell subsets provides the opportunity to improve BCG vaccine efficacy. Recently, we reported that simultaneous inhibition of regulatory T cell (Treg) and Th2 cell responses by immunomodulators in BCG-vaccinated mice promotes T_{CM} cells of the Th1 lineage that protect against M. tuberculosis infection (20). We subsequently showed that inhibition of the potassium channel K_{v1.3}, which is predominantly expressed by T_{EM} cells, by clofazimine enhances T_{CM} responses in BCG-immunized mice and provides long-term protection against TB infection (21). According to WHO guidelines, clofazimine can be used for the treatment of multiple-drug-resistant (MDR) TB. However, clofazimine has serious limitations, which include immune suppression and long-lasting accumulation in various organs (22, 23). Curcumin is known for its immunomodulatory properties and exhibits efficacy against several diseases. However, due to its poor intestinal absorption, rapid metabolism, and rapid systemic elimination, bioavailability is poor, limiting its clinical use. To overcome this limitation, we have generated a nanoparticle-formulated version of curcumin (24). Previously, we reported that our formulation of curcumin nanoparticles possesses five-times-higher bioavailability in mice (24). Here, we explored the immunomodulatory properties of curcumin nanoparticles during BCG immunization and observed a dramatic improvement in the T_{CM}/T_{EM} cell ratios of host-protective Th1 and Th17 cell responses. These properties of curcumin nanoparticles were associated with the upregulation of effector functions in macrophages and dendritic cells. Moreover, these activated antigen-presenting cells (APCs) produced copious amounts of interleukin-12 (IL-12) and NO that promoted bacterial clearance and expansion of memory T cells.

RESULTS
Curcumin nanoparticles enhance the efficacy of BCG immunization in a murine TB model. BCG is the only vaccine commonly used for TB but has limited efficacy in adults. However, it is sufficiently effective against disseminated and meningeal TB in young children (9, 11–13). Therefore, it is likely that host-protective immune responses diminish over time. To explore the immunomodulatory properties of curcumin nanoparticles (nanocurcumin), we performed a series of in vitro experiments with peritoneal macrophages (see Materials and Methods for details). We tested the capacity of nanocurcumin to modulate BCG vaccine efficacy. First, we tested the effects of nanocurcumin on M. tuberculosis H37Rv-infected macrophages. We observed that nanocurcumin treatment of H37Rv-infected peritoneal macrophages reduces the bacterial
burden in a time-dependent fashion (Fig. 1a). Autophagy is the prime mechanism employed by macrophages to eliminate *M. tuberculosis* infection (25). LC3b is a marker that identifies the status of autophagy in cells (25). Therefore, we profiled the percentage of autophagy as well as the activation of macrophages, which revealed that nanocurcumin treatment significantly enhances cellular activation and autophagy (Fig. 1b and c). IL-10 polarizes macrophages toward immunosuppressive phenotypes, whereas tumor necrosis factor alpha (TNF-α) contributes to the activation of macrophages (26, 27). Interferon gamma (IFN-γ) and TNF-α act in conjunction on infected macrophages to induce the production of NO and other free radicals to clear bacteria. IL-10 production downregulates the expression of major histocompatibility complex (MHC) class II (MHCII) and costimulatory molecules, which suppresses protective immune responses. We found that nanocurcumin treatment significantly upregulated the levels of TNF-α and downregulated the levels of IL-10 in H37Rv-infected macrophages (Fig. 1d and e).

After establishing its immunomodulatory properties in vitro, we tested the capacity of nanocurcumin to modulate BCG vaccine efficacy in a murine model of TB. We immunized C57BL/6 mice with BCG subcutaneously and subsequently treated the animals with nanocurcumin for 30 days, followed by a resting period of 30 days. These animals were then aerosol challenged with a virulent strain of H37Rv at a low dose (approximately 110 CFU) (Fig. 2a). The bacterial burdens in lungs and spleen were measured at various time points. We observed that nanocurcumin treatment enhanced BCG vaccine efficacy, as determined by the significant reduction of bacterial loads in both lungs and spleen (Fig. 2b and c). Furthermore, histological studies revealed that nanocurcumin treatment reduced the granulomatous regions in BCG-immunized mice (Fig. 2d).
Nanocurcumin treatment enhances immunity against BCG by modulating innate immune responses. *M. tuberculosis* successfully survives and replicates within phagocytic cells by altering host immune responses (26, 28). *M. tuberculosis* has developed a variety of strategies for this purpose, which include blockade of phagosome maturation and phagolysosome fusion and inhibition of autophagy. It is well known that nanocurcumin induces autophagy in human macrophages and helps in antigen priming of T cells (29–31). *M. tuberculosis* modulates antigen presentation and the expression of costimulatory molecules, which diminishes host-protective immune responses. In accordance with these findings, we found that at 75 days postinfection, nanocurcumin treatment upregulates the function of CD11b⁺ and CD11c⁺ APCs that facilitate T cell priming. We found that the numbers of CD11b⁺ and CD11c⁺ cells were significantly increased in the lungs of animals treated with nanocurcumin during BCG immunization (Fig. 3a). We further found that nanocurcumin treatment enhances the expression of CD86 in both CD11b⁺ and CD11c⁺ cells in lungs of BCG-immunized mice (Fig. 3b), suggesting that nanocurcumin creates an environment conducive for priming and activating T cells. Next, we examined cytokines and effector molecules in macrophages from these animals. We found that nanocurcumin upregulated the expression of inducible nitric oxide synthase (iNOS) and IL-12 (Fig. 3c). In contrast, levels of IL-6 and IL-10 were reduced (Fig. 3c). Therefore, these results indicated that nanocurcumin induces an environment that promotes priming and activation of host-protective T cells during BCG immunization.

**Nanocurcumin treatment increases the proliferation and activation of antigen-specific CD4⁺ and CD8⁺ T cells in BCG-immunized animals.** The activation of CD11b⁺ and CD11c⁺ cells in nanocurcumin-treated animals prompted us to examine possible alterations in T lymphocyte responses. It is well established that both CD4⁺ and CD8⁺ T cells play important roles in host resistance against TB (32). Antigen-specific CD4⁺ T cells producing IFN-γ and TNF-α act on infected macrophages to...
promote bacterial clearance via autophagy (25). To determine whether nanocurcumin treatment increases the activation and proliferation of T cells in BCG-immunized mice, we injected animals with bromodeoxyuridine (BrdU) prior to sacrifice at 75 days postinfection. Splenocytes were harvested and challenged with *M. tuberculosis*-derived complete soluble antigen (CSA) to estimate antigen-specific activation and proliferative responses. Our results demonstrated that splenocytes from BCG-immunized mice that received nanocurcumin treatment exhibited increased proliferative responses for both CD4$^+$ and CD8$^+$ T cells compared with the other experimental groups of mice (Fig. 4a and b). Consistent with these findings, both CD4$^+$ and CD8$^+$ T cells upregulated the early activation marker CD69 in nanocurcumin- and BCG-treated mice (Fig. 4c and d). These results suggested that nanocurcumin treatment increased the proliferation and activation of both CD4$^+$ and CD8$^+$ T cells in BCG-immunized mice.

**Nanocurcumin improves the T<sub>CM</sub>-to-T<sub>EM</sub> cell ratio in BCG-immunized mice.**

Long-term vaccine efficacy primarily depends upon the ratio of T<sub>CM</sub> to T<sub>EM</sub> cells generated during infection (15, 19). Previous studies have shown that BCG does not induce sufficient levels of T<sub>CM</sub> cells in lungs and spleen (16–18). Therefore, a strategy that enhances T<sub>CM</sub> responses may provide improved vaccine efficacy. K<sub>v</sub>1.3 is a potassium channel predominantly expressed on T<sub>EM</sub> cells and is required for the differentiation of T<sub>CM</sub> cells into T<sub>EM</sub> cells (33, 34). Hence, blocking the K<sub>v</sub>1.3 channel may amplify CD4$^+$ and CD8$^+$ T<sub>CM</sub> cells. In fact, such a blockade has recently been shown to increase T<sub>CM</sub> cells (21, 35). Nanocurcumin blocks the K<sub>v</sub>1.3 channel and is effectively distributed to lungs and spleen. Therefore, to elucidate the effect of K<sub>v</sub>1.3 blockade by nanocurcumin on BCG immunization, we analyzed the phenotype of T<sub>CM</sub> and T<sub>EM</sub> cells by flow cytometry 75 days after aerosol challenge. We found that nanocurcumin...
treatment in BCG-immunized mice yielded higher numbers of TCM (CD44hi CD62Lhi and CD44hi CCR7hi) cells than TEM (CD44hi CD62Llow and CD44hi CCR7low) cells in the CD4+ T cell subset (Fig. 5a and b) than in BCG-immunized and unimmunized mice. A similar trend in the prevalence of TCM (CD44hi CD62Lhi and CD44hi CCR7hi) and TEM (CD8+ CD44hi CD62Llow and CD44hi CCR7low) populations was found for CD8+ T cells (Fig. 5b and d). Interestingly, the magnitude of the increase in CD8+ TCM cells was more pronounced than for CD4+ TCM cells. Next, we examined the status of memory T cells in lungs and found a trend similar to that in the spleen (Fig. 6). Therefore, nanocurcumin treatment modulates T lymphocyte memory responses, especially the TCM cell pool. This enhanced TCM/TEM cell ratio induced by nanocurcumin treatment might provide long-term protection from TB (see Table S1 in the supplemental material).

Nanocurcumin promotes antigen-specific, host-protective immune responses in BCG-immunized mice. Our finding that nanocurcumin enhances the TCM/TEM cell ratio prompted us to assess the cytokine production profile of T cells. It is well established that Th1 responses are indispensable for host protection against TB, and emerging evidence indicates an important role for Th17 cells as well (36). As Th cell subsets are in a dynamic balance, Th2 and Treg responses are enhanced after M. tuberculosis infection, which inhibits host-protective Th1 and Th17 responses. Hence, long-term protection is possible only by blocking these unfavorable T cell responses.
Recently, we have shown that simultaneous inhibition of Th2 cells and Tregs not only favors Th1 responses but also promotes TCM responses (20). Therefore, enhancing BCG vaccine efficacy may be achieved by enhancing both Th1 and Th17 responses and simultaneously suppressing Th2 and Treg responses. Nanocurcumin satisfies these criteria and, hence, could be useful in enhancing BCG vaccine efficacy. To elucidate the effect of nanocurcumin treatment on immune responses elicited following BCG immunization, splenocytes were stimulated with *M. tuberculosis*-derived CSA, and the frequencies of CD4+ T cells producing the signature cytokines associated with Th1 (IFN-γ), Th2 (IL-4), and Th17 (IL-17) cells were determined. Our observations demonstrated that nanocurcumin treatment in BCG-immunized mice significantly increased IFN-γ-producing Th1 and IL-17-producing Th17 cells, whereas the levels of IL-4-producing Th2 cells were moderately decreased (Fig. 7a). Because CD4+ CD25+ Foxp3+ Tregs favor disease pathogenesis, we also measured the status of these cells (CD4+ CD25+ Foxp3+). Remarkably, we found a significant decrease of Tregs in nanocurcumin-treated, BCG-immunized mice compared with BCG-immunized and untreated animals (Fig. 7b).

To identify the innate cytokines that are responsible for this biased T cell polarization, we determined the levels of IL-2, TNF-α, and transforming growth factor β (TGF-β)-producing cells (Fig. 7c and Fig. S1). IL-2, IFN-γ, and TNF-α are hallmarks of polyfunctional memory cells (37). We found that levels of TNF-α and IL-2-producing cells were increased, with a concomitant increase in the level of IFN-γ-producing cells.
These results indicated that nanocurcumin treatment enhances Th1 and Th17 cell responses but restricts Th2 cell and Treg responses in BCG-immunized mice.

DISCUSSION

*M. tuberculosis* evades host immune responses in part by altering the balance of T cell responses. BCG is the only TB vaccine available, but its efficacy in preventing adult pulmonary TB is limited, varying from 0 to 80%, depending on the ethnicity and geographical location of the vaccinated population (11–14). Although the precise immune responses required for optimal host protection are still unclear, it is well established that Th1 and Th17 responses play key roles, whereas Th2 cells and Tregs promote disease progression by inhibiting host-protective Th1 and Th17 responses (20, 36). BCG induces adequate levels of IFN-γ-producing T cells in the host but generates only a few IL-17-producing T cells. Moreover, recent studies have shown that CD4+ cell-derived IFN-γ is not the limiting factor, as excessive levels of IFN-γ may have deleterious inflammatory effects (38). Concurrently, BCG induces TGF-β and IL-10 production, which facilitates Treg and Th2 cell differentiation (39–41). Additionally, mesenchymal stem cells (MSCs) also induce Tregs and suppress protective immune responses (42, 43). APCs such as macrophages and dendritic cells engulf the bacteria at the site of infection and subsequently migrate to secondary lymphoid organs. These cells also upregulate costimulatory molecules, produce proinflammatory cytokines, and...
present antigens to T cells, which then differentiate into distinct effector cell subsets (26). BCG immunization induces IL-10 production, which downregulates the expression of MHC class II and costimulatory molecules (44–47), limiting the efficacy of the BCG vaccine. It was previously reported that inhibition of IL-10 increases the efficacy of BCG (48). Our results demonstrate that the addition of nanocurcumin to the BCG vaccine inhibits the production of immunosuppressive cytokines, such as IL-10, in infected macrophages.

Vaccine efficacy is critically dependent on T helper memory subsets. TEM cells have a limited capacity to proliferate and differentiate but quickly respond to antigenic challenge by converting into terminal effector cells. On the other hand, TCM cells are capable of extensive proliferation, are comparatively less differentiated than TEM cells, and persist for only a short time period. In response to antigenic challenge, many TCM cells differentiate into effector cells, some differentiate into TEM cells (15), and some cells retain their TCM phenotype for future immune responses. TCM cells have the ability to respond to two types of signals: (i) homeostatic signals for self-renewal and (ii) antigen-specific signals for differentiation into TEM cells. BCG induces antigen-specific TEM cells and limited levels of TCM cells (19). Moreover, although BCG induces sufficient numbers of TCM cells in the lungs to permit the generation of TEM cells, these cells become gradually exhausted due to continuous exposure to environmental mycobacteria found in countries with a high TB burden (21). Therefore, the ratio of TCM to TEM cells is critically important for BCG vaccine efficacy. Our study revealed that nanocurcumin increases the TCM pool without substantially altering the TEM pool, which significantly improved the ratio of TCM over TEM responses in BCG-immunized animals.
Our results implied that nanocurcumin treatment effectively activated APCs by upregulating costimulatory molecules, induced IL-12 and iNOS production, and reduced the production of IL-10 in APCs. We propose that these alterations induced by nanocurcumin established a physiological environment conducive for the generation of protective T cell responses against TB (26, 49–52).

In addition to its effects on APCs, in vivo T cell activation and proliferation studies with BrdU clearly demonstrated that nanocurcumin enhanced the proliferation of CD4 and CD8 T cells in BCG-immunized animals. In this context, it was previously established that nanocurcumin prevents AICD (activation-induced cell death) of antigen-specific T cells induced during directly observed treatment, short term (DOTS) (53). Therefore, nanocurcumin enhances adaptive immune responses by inducing \( M. tuberculosis \)-specific activated T cells.

Curcumin blocks the K\(_{\text{V}}\),1.3 potassium channel (54), which is predominantly expressed on T\(_{\text{EM}}\) cells (35, 55). Although T\(_{\text{EM}}\) cells play a role in bacterial clearance, they are also the major cause of tissue-specific inflammation (56). A number of studies have shown that K\(_{\text{V}}\),1.3 blockade can inhibit inflammation in a variety of diseases (23). Moreover, K\(_{\text{V}}\),1.3 loss of function in mice causes a delay in T\(_{\text{CM}}\)-to-T\(_{\text{EM}}\) cell conversion and promotes the generation of a pool of long-lasting T\(_{\text{CM}}\) cells (57). Consistent with these findings, we found that nanocurcumin increased the pool of CD4\(^+\) and CD8\(^+\) T\(_{\text{CM}}\) cells in spleen and lungs. No significant changes were observed in T\(_{\text{EM}}\) cells, indicating that nanocurcumin inhibits the conversion of T\(_{\text{CM}}\) to T\(_{\text{EM}}\) cells and increases the T\(_{\text{CM}}\)/T\(_{\text{EM}}\) cell ratio, thereby enhancing BCG vaccine efficacy and reducing disease pathology.

**Conclusion.** Altogether, we have shown that nanocurcumin activates the innate part of the immune response to induce costimulatory molecules and proinflammatory cytokines in APCs. Simultaneously, it also increases autophagy in APCs. These findings are consistent with the enhanced antigen-presenting capacity of nanocurcumin-treated APCs (29). In the adaptive part of the immune response, nanocurcumin restricts the conversion of T\(_{\text{CM}}\) to T\(_{\text{EM}}\) cells to increase the T\(_{\text{CM}}\) pool for the establishment of long-term memory responses to the BCG vaccine. Additionally, nanocurcumin protects tissues against uncontrolled inflammation. The precise molecular mechanism by which nanocurcumin enhances APC and T cell functions will require further studies.

**MATERIALS AND METHODS**

**Ethics statement.** All animal experiments were performed in accordance with the guidelines approved by the Meeting of the Institutional Animals Ethics Committee, held at the Jawaharlal Nehru University (JNU), approval code no. 19/2014, and also at the International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India (approval no. ICGEB/IAEC/08/2016/TACF-JNU). We also followed guidelines issued by the Department of Biotechnology, Government of India. All mice used for experiments were ethically euthanized by asphyxiation in carbon dioxide according to institutional and Department of Biotechnology regulations.

**Mice.** Six- to eight-week-old female C57BL/6 mice were purchased from the animal house facility of the ICGEB. All mice used for experiments were housed under barrier conditions in the Tuberculosis Aerosol Challenge Facility (TACF) of the ICGEB and treated humanely according to specified animal care protocols of TACF and ICGEB guidelines.

**Preparation of curcumin nanoparticles.** Nanocurcumin was prepared according to methods described in our previous report (24). Briefly, 10 g of curcumin (Sigma, USA) was dissolved in 2.5 liters of distilled ethanol at room temperature and filtered to obtain a clear solution. This solution was then stirred in a high-speed homogenizer (T 25 digital Ultra-Turrax) at 12,000 to 15,000 rpm, and the required volume of Milli Q water containing 0.1% citric acid (Merck, India) was added to it slowly over a period of 1 h until the ethanol concentration reached 40% (vol/vol) and curcumin particles started to precipitate from the solution. The entire suspension was then homogenized over ice in a high-pressure homogenizer (Avestin Cs high-pressure homogenizer) at 30,000 lb/in\(^2\) for 30 cycles. The aqueous suspension was then homogenized over ice in a high-pressure homogenizer (Avestin Cs high-pressure homogenizer) at 30,000 lb/in\(^2\) for 30 cycles. The aqueous suspension was then transferred to a high-speed homogenizer (T 25 digital Ultra-Turrax) at 12,000 to 15,000 rpm and homogenized again for 1 h, and filtered. The filtered slurry was dried at 80°C in an oven to obtain curcumin powder. The particle size was determined by using a high-resolution transmission electron microscope (JEM 2100F; JEOL, USA).

**Bacterial culture.** All mycobacterial strains were grown in 7H9 medium (Middlebrook; Difco) supplemented with 10% albumin, dextrose, and catalase enrichment medium (OADC; Difco, USA) with
0.05% Tween 80 and 0.2% glycerol, and cultures were grown to mid-log phase. Aliquots of the cultures in 20% glycerol were preserved at −80°C, and these cryopreserved stocks were used for infections.

**BCG immunization experiments.** Mice were immunized subcutaneously with 1 × 10⁶ CFU of BCG in 100 µl of sterile phosphate-buffered saline (PBS). After 1 day of rest, these mice were treated with curcumin nanoparticles at 10 mg/kg of body weight every day in 100 µl of PBS, administered intraperitoneally (i.p.) for a total of 30 days. Mice were subsequently rested for 30 days. They were then challenged via the aerosol route with *M. tuberculosis* strain H37Rv, as described below, and organs were harvested after euthanasia to determine the bacterial burden and for immunophenotyping at different time points. For lymphocyte proliferation assays, mice were sacrificed 75 days after aerosol challenge. Seventy-two hours prior to sacrifice, animals were injected intraperitoneally with BrdU (Sigma) dissolved in 100 µl of PBS.

*M. tuberculosis* low-dose aerosol infection of mice. *M. tuberculosis* strain H37Rv (ATCC 27294; American Type Culture Collection) was a kind gift from Colorado State University. Mouse infections were performed in accordance with the low-dose aerosol infection model, using a Madison aerosol chamber (University of Wisconsin, Madison) with the nebulizer precalibrated at approximately 90 to 120 CFU per mouse. For aerosol infection, cultures were washed twice with PBS and made into a single-cell suspension by passage through a 26-gauge needle 10 times. Next, 15 ml of the *M. tuberculosis* H37Rv single-cell suspension (100 × 10⁶ cells) was placed into the nebulizer reservoir of the Madison aerosol chamber, calibrated to deliver the desired CFU of bacteria into the lungs of mice kept in the chamber in 15-min cycles. Twenty-four hours after aerosol challenge, 3 mice were euthanized for quantitation of pathogen delivery to lungs by measurement of CFU in lung homogenates. Mice were found to be infected with approximately 110 CFU of *M. tuberculosis* in their lungs. The mice were maintained under biosafety level 3 containment thereafter.

**Quantification of pathogen burden by CFU counts.** Randomly selected mice were euthanized at various time points, after which organs were harvested and homogenized in 0.2-µm-filtered PBS. Lungs and spleen cell homogenates were plated on 7H11 plates containing 10% OADC and incubated at 37°C for approximately 21 days. CFU were counted, and the pathogen burdens in lungs and spleen were estimated.

**In vitro experiments with peritoneal macrophages.** Six- to eight-week-old C57BL/6 mice were given an i.p. injection of 1 ml thioglycolate medium (4%). After 5 days, macrophages were obtained by peritoneal lavage. Macrophages were washed once with cold PBS and suspended in cold RPMI 1640 medium. Cells were counted, seeded on 12-well plates, and maintained at 37°C in RPMI 1640 medium supplemented with penicillin-streptomycin (1,000 U/ml) and 10% heat-inactivated fetal calf serum. After overnight incubation, nonadherent cells were washed off. Adherent cells were infected with H37Rv at a ratio of 10:1. Cells were then treated with 60 nM curcumin nanoparticles and kept at 37°C in a CO₂ incubator. After 24 and 48 h of infection, macrophages were harvested for CFU determination and flow cytometry.

**Flow cytometry.** (i) Surface and intracellular staining of peritoneal macrophages. After 48 h of infection, peritoneal macrophages were harvested for flow cytometry. Four to six hours prior to staining, phorbol myristate acetate (PMA) (50 ng/ml) and ionomycin (750 ng/ml) were added to the cultures. Moreover, brefeldin A was also added to these cultures at this time point for intracellular staining, as described below.

(ii) Surface and intracellular staining of in vivo samples. Spleens and lungs were isolated from mice and macerated by using frosted slides in ice-cold RPMI 1640 medium (Gibco, Invitrogen) containing 10% fetal bovine serum to prepare a single-cell suspension. Red blood cells were lysed with lysis buffer by incubation at room temperature for 1 to 2 min and then washed with RPMI 1640 medium. The cells were counted, and 1 × 10⁶ cells per well were cultured for staining in 12-well plates. Lymphocytes were stimulated with H37Rv complete soluble antigen (CSA) and cultured overnight before staining. For staining of antigen-presenting cells, no such CSA challenge was performed. Before staining, cells were washed twice with fluorescence-activated cell sorter (FACS) buffer and then stained with antibodies directed against surface markers. After the addition of antibodies, cells were kept for 40 min at room temperature for optimum staining. Next, cells were washed again with buffer and resuspended in FACS buffer. For intracellular staining, lymphocytes (2 × 10⁶ cells) were cultured in 12-well plates and stimulated with H37Rv complete soluble antigen overnight, with 5 µg/ml of brefeldin A (BioLegend) being added during the last 6 h of culture. For intracellular staining, cells were fixed after surface staining with 100 µl of fixation buffer (BioLegend) for 30 min and then washed twice with permeabilization buffer (BioLegend), resuspended in 200 µl of permeabilization buffer (BioLegend), and stained with fluorescently labeled antibodies. After staining, cells were washed again with FACS buffer and resuspended in FACS buffer. The fluorescence intensity of fluorochrome-labeled cells was measured by flow cytometry (FACS-LSR Fortessa; BD Biosciences). BD FACSDiva software was used to acquire the cells, and data analysis was performed using FlowJo software (TreeStar).

**Histological studies.** Pieces of lungs from mice 75 days after infection were perfused, removed, fixed in 4.5% formalin for 12 h, and transferred to 70% ethanol; paraffin blocks were then made; and 6-µm sections were cut and stained with hematoxylin and eosin according to our previous work (58).

**Statistical analysis.** All data were derived from ≥3 independent experiments. Statistical analyses were conducted using GraphPad software, and values are presented as means with standard deviations (SD). Significant differences between the group means were determined by analysis of variance (ANOVA) with Tukey’s post hoc analysis. Differences were considered statistically significant at a *P* value of <0.05.
SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at https://doi.org/10.1128/IAI.00291-19.

SUPPLEMENTAL FILE 1, PDF file, 0.1 MB.

ACKNOWLEDGMENTS

We acknowledge the support of the Department of Biotechnology-supported Tuberculosis Aerosol Challenge Facility at the ICGEB and their staff in accomplishing this work. We thank the SCMM (JNU) and the ICGEB, New Delhi, where the work was accomplished. We also thank Sultan Tausif and Samit Chattarjee for their kind support.

This work was supported by the Department of Biotechnology, Government of India (grant BT/PR6312/MED/29/605/2012), DST Purse Phase-II, SCMM (core research grant), and the Council of Scientific and Industrial Research (CSIR), which provided a Junior Research Fellowship and a Senior Research Fellowship to Shaheer Ahmad and a Senior Research Associateship to Debapriya Bhattacharya (pool scientist scheme; pool no. 8802/A).

S.A. and D.B. designed the experiments, did the work, analyzed it, and wrote the paper. S.K. prepared nanopercumin and determined its bioavailability and size. Moreover, he also helped in writing the manuscript. A.R. and L.V.K. helped in editing the experiments, analyzed the data, and wrote the paper.

All authors have submitted the ICMJE form for disclosure of potential conflicts of interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

REFERENCES

1. WHO. 2010. WHO global tuberculosis control report 2010. Summary. Cent Eur J Public Health 18:237.
2. Pawlowski A, Jansson M, Skold M, Rottenberg ME, Kallenius G. 2012. Tuberculosis and HIV co-infection. PLoS Pathog 8:e1002464. https://doi.org/10.1371/journal.ppat.1002464.
3. Zumla A, Raviglione M, Hafer R, von Reyn CF. 2013. Tuberculosis. N Engl J Med 368:745–755. https://doi.org/10.1056/NEJMra1200894.
4. Getahun H, Gunneberg C, Granich R, Nunn P. 2010. HIV infection-associated tuberculosis: the epidemiology and the response. Clin Infect Dis 50(Suppl 3):S520–S527. https://doi.org/10.1086/651492.
5. Collins KR, Quinones-Mateu ME, Toossi Z, Arts EJ. 2002. Impact of tuberculosis on HIV-1 replication, diversity, and disease progression. AIDS Rev 4:165–176.
6. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C. 2003. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 163:1009–1021. https://doi.org/10.1001/archinte.163.9.1009.
7. Mutis T, Cornelisse YE, Ottenhoff TH. 1993. Mycobacteria induce CD4+ T cells that are cytotoxic and display Th1-like cytokine secretion profile: heterogeneity in cytokotic activity and cytokine secretion levels. Eur J Immunol 23:2189–2195. https://doi.org/10.1002/eji.1830230921.
8. Haenen JB, de Waal Malefijt R, Res PC, Kraakman EM, Ottenhoff TH, de Vries RR, Spits H. 1991. Selection of a human T helper type 1-like T cell subset by mycobacteria. J Exp Med 174:583–593. https://doi.org/10.1084/jem.174.3.583.
9. Bhattacharya D, Dwivedi VP, Maiga M, Maiga M, Van Kaer L, Bishai WR, Das G. 2014. Small molecule-directed immunotherapy against recurrent infection by Mycobacterium tuberculosis. J Biol Chem 289:16508–16515. https://doi.org/10.1074/jbc.M114.558098.
10. Ravindran R, Krishnan WW, Khanum A, Luciw PA, Khan IH. 2013. Exploratory study on plasma immunomodulator and antibody profiles in tuberculosis patients. Clin Vaccine Immunol 20:1283–1290. https://doi.org/10.1128/CVI.00213-13.
11. Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson ME, Burdick E, Fineberg HV. 1995. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 96:29–35.
12. Colditz GA, Brewer TF, Berkey CS, Van Kaer L, Burdick E, Fineberg HV, Mosteller F. 1994. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271:698–702. https://doi.org/10.1001/jama.1994.03510330076038.
13. Brewer TF. 2000. Preventing tuberculosis with bacillus Calmette-Guerin vaccine: a meta-analysis of the literature. Clin Infect Dis 31(Suppl 3):S64–S67. https://doi.org/10.1086/314072.
14. Soysal A, Millington KA, Bakir M, Dosanjh D, Aslan Y, Deeks JJ, Efe S, Staveley I, Ewer K, Lalvani A. 2005. Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet 366:1443–1451. https://doi.org/10.1016/S0140-6736(05)67544-4.
15. Ahlers JD, Belyakov IM. 2010. Memories that last forever: strategies for optimizing vaccine T-cell memory. Blood 115:1678–1689. https://doi.org/10.1182/blood-2009-06-227546.
16. Masopust D, Ha SJ, Veysz V, Ahmed R. 2006. Stimulation history dictates memory CD8 T cell phenotype: implications for prime-boost vaccination. J Immunol 177:831–839. https://doi.org/10.4049/jimmunol.177.2.831.
17. Wirth TC, Xue HH, Rai D, Sabel JT, Bair T, Harty JT, Badovinac VP. 2010. Repetitive antigen stimulation induces stepwise transcriptive diversification but preserves a core signature of memory CD8(+) T cell differentiation. Immunity 33:128–140. https://doi.org/10.1016/j.immuni.2010.06.014.
18. Wirth TC, Harty JT, Badovinac VP. 2010. Modulating numbers and phenotype of CD8+ T cells in secondary immune responses. Eur J Immunol 40:1916–1926. https://doi.org/10.1002/eji.201040310.
19. Henao-Tamayo MI, Ordway DJ, Irwin SM, Shang S, Shanky CM, Orme IM. 2010. Phenotypic definition of effector and memory T-lymphocyte subsets in mice chronically infected with Mycobacterium tuberculosis. Clin Vaccine Immunol 17:618–625. https://doi.org/10.1128/CVI.00368-09.
20. Bhattacharya D, Dwivedi VP, Kumar S, Reddy MC, Van Kaer L, Moodley P, Das G. 2014. Simultaneous inhibition of T helper 2 and T regulatory cell differentiation by small molecules enhances bacillus Calmette-Guerin vaccine efficacy against tuberculosis. J Biol Chem 289:33404–33411. https://doi.org/10.1074/jbc.M114.600452.
21. Singh DK, Dwivedi VP, Ranganathan A, Bishai WR, Van Kaer L, Das G. 2016. Blockade of the Kvl.3 K+ channel enhances BCG vaccine efficacy by expanding central memory T lymphocytes. J Infect Dis 214:1456–1464. https://doi.org/10.1093/infdis/jiw395.
22. Jean D. 2017. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update: applicability in South Korea. Tuberc Respir Dis 80:336–343. https://doi.org/10.4046/trd.2017.0049.

23. Gocke AR, Lebson LA, Grishkan IV, Lu L, Nguyen HM, Whartenby KA, Chandy KG, Calabrese PA. 2012. Kv.1. deletion biases T cells toward an immunoregulatory phenotype and renders mice resistant to autoimmune encephalomyelitis. J Immunol 188:5877–5886. https://doi.org/10.4049/jimmunol.1103095.

24. Tousif S, Singh DK, Mukherjee S, Ahmad S, Arya R, Nanda R, Ranganathan A, Bhattacharyya M, Van Kaer L, Kar SK, Das G. 2017. Nanoparticle-formulated curcumin prevents posttherapeutic disease reactivation and reinfection with Mycobacterium tuberculosis following isoniazid therapy. Front Immunol 8:739. https://doi.org/10.3389/fimmu.2017.00739.

25. Deretic V. 2014. Autophagy in tuberculosis. Cold Spring Harb Perspect Med 4:a018481. https://doi.org/10.1101/cshperspect.a018481.

26. Flynn JL, Chan J. 2001. Immunology of tuberculosis. Annu Rev Immunol 19:93–129. https://doi.org/10.1146/annurev.immunol.19.1.93.

27. Benoit M, Desnues B, Mege JL. 2008. Macrophage polarization in bacterial infections. J Immunol 181:3733–3739. https://doi.org/10.4049/jimmunol.181.6.3733.

28. Lerner TR, Borel S, Gutierrez MG. 2015. The innate immune response in human tuberculosis. Cell Microbiol 17:1277–1285. https://doi.org/10.1111/cmi.12480.

29. Bai X, Oberley-Deegan RE, Bai A, Ovrutsky AR, Kinney WH, Weaver M, Zhang G, Honda JR, Chan ED. 2016. Curcumin enhances human macrophage control of Mycobacterium tuberculosis infection. Respiratory 21:951–957. https://doi.org/10.1111/resp.12762.

30. Trinchieri G. 1993. Interleukin-12 and its role in the generation of TH1 cells. Immunol Today 14:335–338. https://doi.org/10.1016/0167-5699(93)90230-I.

31. Bai X, Oberley-Deegan RE, Bai A, Ovrutsky AR, Kinney WH, Weaver M, Zhang G, Honda JR, Chan ED. 2016. Curcumin enhances human macrophage control of Mycobacterium tuberculosis infection. Respiratory 21:951–957. https://doi.org/10.1111/resp.12762.

32. Trinchieri G. 1993. Interleukin-12 and its role in the generation of TH1 cells. Immunol Today 14:335–338. https://doi.org/10.1016/0167-5699(93)90230-I.

33. Trinchieri G. 1993. Interleukin-12 and its role in the generation of TH1 cells. Immunol Today 14:335–338. https://doi.org/10.1016/0167-5699(93)90230-I.

34. Trinchieri G. 1993. Interleukin-12 and its role in the generation of TH1 cells. Immunol Today 14:335–338. https://doi.org/10.1016/0167-5699(93)90230-I.

35. Tousif S, Singh DK, Mukherjee S, Ahmad S, Arya R, Nanda R, Ranganathan A, Bhattacharyya M, Van Kaer L, Kar SK, Das G. 2017. Nanoparticle-formulated curcumin prevents posttherapeutic disease reactivation and reinfection with Mycobacterium tuberculosis following isoniazid therapy. Front Immunol 8:739. https://doi.org/10.3389/fimmu.2017.00739.

36. Gattinoni L, Speiser DE, Lichterfeld M, Bonini C. 2017. T memory stem cell population during the differentiation process of Th1 and Th17 cells. Proc Natl Acad Sci U S A 114:235–238. https://doi.org/10.1073/pnas.1601340.

37. Gattinoni L, Speiser DE, Lichterfeld M, Bonini C. 2017. T memory stem cell population during the differentiation process of Th1 and Th17 cells. Proc Natl Acad Sci U S A 114:235–238. https://doi.org/10.1073/pnas.1601340.

38. Barber DL. 2016. CD4 T cell-derived IFN-gamma plays a minimal role in reinfection with Mycobacterium tuberculosis following isoniazid therapy. Mucosal Immunol 9:3:e4009. https://doi.org/10.1038/mucim.2015.109.

39. Kuchroo VK. 2006. Reciprocal developmental pathways for the generation of IL-21- and IFN-gamma-co-expressing polyfunctional CD4+ T cells from human naive CD4+ T cells. Cell Cycle 14:3362–3372. https://doi.org/10.1080/15384101.2015.1093703.

40. Cooper AM, Solache A, Khader SA. 2007. Interleukin-12 and tuberculosis: implications for the immunological response in tuberculosis patients coinfected with HIV. Front Immunol 8:1120. https://doi.org/10.3389/fimmu.2017.01120.